Johnson & Johnson JNJ

$257.78 -1.58 (-0.61%)

Valuation

Market cap
625,031,104,000
Revenue TTM
$94,193,000,000
Net income TTM
$26,804,000,000
PE ratio
23.83
Forward PE
22.83
Profit margin
28.46%
Debt to equity
0.44

Trading

Volume
6,557,000
Avg volume
6,844,928
Day's range
$254.56 – $257.80
Shares out
2,409,898,000
Stochastic %K
66%
Beta
0.21
Analysts
Strong Sell
Price target
$282.24

Price

Company profile

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular...

Show more

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
732 524 0400
Website
https://www.jnj.com
Address
One Johnson & Johnson Plaza, New Brunswick, United States

Latest news

Stocktwits

Fliptax Oct 22, 2:44 PM
$PFE https://www.fiercebiotech.com/biotech/pfizer-inks-500m-enodia-pact-join-lilly-emerging-protein-degrader-field $MRNA $JNJ $LLY
0 replies
SellasgpsCurativeBAT11 Oct 22, 2:41 PM
$AZN $JNJ $MRK $PFE $SLS 2 Late Stage Cancer Platforms GPS and SLS009. NO official PR for a month. No show at one of the biggest Oncology healthcare conference in Europe. No lease extension. Over 1 million RSu’s granted to Dr. Stergiou. Golden Parachutes for the entire executive team with cash payments upon change of control. Dr. Stergiou next chapter Linkedln post. You have to close one chapter to bring a best New chapter. ✌️🙏❤️‍🩹
0 replies
SellasgpsCurativeBAT11 Oct 22, 2:32 PM
$SLS $PFE $MRK $AZN $JNJ Keith, with record $139 Million in cash the biggest in Sellas corporate history since inception. Sellas doesn’t show up at ESMO = BO coming any hour now. Mark this post. 1. The "Exclusivity Gag" (Why IR is Dead) Total silence from official corporate channels is the strongest indicator that a binding exclusivity agreement is in place. The No-Shop Clause: Once a core bidder is selected for final negotiations, the company is legally prohibited from soliciting other offers or issuing PR that could "pump" the stock. The Strategic Blackout: To avoid any risk of breaching the agreement or "gun-jumping" before the Phase 3 readout, the lawyers shut down the IR department. Official silence confirms the deal is at the finish line and the "lock-shop" period is active. ✌️🙏❤️‍🩹
0 replies
HboFam Oct 22, 2:29 PM
$ SLS $AZN $BMY $JNJ @SellasgpsCurativeBAT11 a fake pump bot the bogus billionaire biostatistician pumps are all a set up for another short rug pull when the 80th is announced kalshi odds 100% on @SellasgpsCurativeBAT11 lying pos, tony the tiger will be so scared he's gonna sell it all After the 80th
0 replies
SellasgpsCurativeBAT11 Oct 22, 2:24 PM
$AZN $BMY $JNJ $PFE $SLS If Sellas don’t show up at ESMO. Next PR could very well be an Outright BO! ✌️🙏❤️‍🩹
0 replies
TopOptionAlert Oct 22, 2:22 PM
$JNJ NOV20 265C · update Called at $255.56 on Oct 19, now $263.28 (plus 3.02%). The trade is working, with objectives at $264.39, then $281.07, and the invalidation at $245.17. P.S. Watch $264.39 from here, friend, because that first objective is close now and a close over it would open the way toward $281.07.
0 replies
SellasgpsCurativeBAT11 Oct 22, 2:19 PM
$AZN $BMY $JNJ $PFE $SLS ESMO Congress 2026 starts tomorrow. 🤐 The ESMO 2026 Congress will take place from 23 to 27 October 2026, in Madrid, Spain, with sessions also available through a dedicated virtual platform. Sellas has been known to show up at conferences un announced. 😉 ✌️🙏❤️‍🩹
0 replies
BarkingPuppy Oct 22, 2:10 PM
$JNJ $PFE $MRNA Which big pharma is buying Elite ????? I know they are shopping...
0 replies